To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson’s disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
CaV1.3 Antibody
Antibody
Rabbit monoclonal antibody directed against human/mouse CaV1.3. Developed for use in immunoblotting, immunocytochemistry, immunohistochemistry, and immunoprecipitation applications.
This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2027
EEA1 Edited Endo-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged EEA1 for Endo-IP.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative.
Estimated Availability: late 2026
OMP25 Edited Mito-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged OMP25 for Mito-IP.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative.
Estimated Availability: late 2026
TMEM192 Edited Lyso-IP iPSC Line
Human iPS Cell
KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged TMEM192 for Lyso-IP.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative.
Estimated Availability: late 2026
STING1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of STING1.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Estimated Availability: Late 2026
TLR2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous knockout of TLR2.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Estimated availability: late 2026
USP30 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered heterozygous and homozygous of USP30.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Estimated availability: late 2026
Alpha-Synuclein O-GlcNAc T72 Antibody
Antibody
Rabbit monoclonal antibody specific to human and mouse alpha-synuclein when modified with O-GlcNAc at Threonine 72 (O-GlcNAc T72 aSyn). Developed for use in immunoblotting, immunofluorescence, and ELISA applications.
This antibody development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Anticipated Availability: Q4 2027
MAPT Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including heterozygous knockout.
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Estimated Availability: Late 2026
TRPML1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in TRPML1, including
- -F408* (heterozygous and homozygous) - in development, est late 2026
- -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026
These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD).This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative.
Have questions or need additional information?
Email [email protected] with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic